MAY. 18. 2005 11:46AM TO: US USPTO GENERAL

AVENTIS US PAT DEPT

RECEIVED **CENTRAL FAX CENTER**

NO. 5341 P. 1

MAY 1 8 2005

,		U.S.	Datant and T	andament All	PTC/SB/21 (09-04) ise through 07/31/2006. OMB 0651-0031 a; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995	no person.	s are required to respond to a co Application Number	illection of inf	ormation unle	a it displays a valid OMB control number.
TRANSMITTAL		Filing Date	10/719,0		
FORM		First Named Inventor		er 21, 200	·
PORIVI		Art Unit	1626	GRAUPE	et al
		Examiner Name			
(to be used for all correspondence after initial		Attorney Docket Number	Anderso		
Total Number of Pages in This Submission	16	Attorney Docker (volitide)	USAV20	001/0082 U	S CNT
	ENCL	OSURES (Check all	that apply)	
Fee Transmiltal Form Fee Attached		Drawing(s) _icensing-related Papers		Ap	er Allowance Communication to TC leaf Communication to Board ppeals and Interferences
Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53		Petition Petition to Convert to a Provisional Application Power of Attorney, Revocatio Change of Correspondence A Ferminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CD ks	Address	Pro Sta	eal Communication to TC peal Notice, Brief, Reply Brief) prietary Information tus Letter er Enclosura(s) (please Identify w): Form 1449
	TURE O	F APPLICANT, ATTO	RNEY, O	R AGENT	
AVENTIS PHARMACE	UTICAL	S INC.			
Signature Healen.	Ru	Li.			
Printed name Joseph MOSSI					
Date May 18, 2005		F	Reg. No.	47038	
I hereby certify that this correspondence is be sufficient postage as first class mail in an em	eina facsin	ATE OF TRANSMISSI	O or deposi	ted with the	United States Postal Service with
the date shown below: (USPTO FAX NO. 70)3-872-9	306 ; Total No. of Pag)
fo			·		
Typed or printed name Paul Irvine		•		Dat	May 18, 2005

This collection of information is required by 37 CFR 1.5. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Dopartment of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Title:

冈

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of GRAUPE, et al.

Examiner:

Anderson, R.L.

Olcaol E, et al.

Art Unit:

1626

Application No.: 10/719,080

TELEFAX CERTIFICATE

Filed: November 21, 2003

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, on

NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN

INHIBITORS

May 18, 2005

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(b), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

(b)	This	s Information Disclosure Statement is filed after the period set forth in 37 C.F.R.
	1.97	(b), but is believed to be filed before the mailing date of a final action under §1.113
	or a	notice of allowance under §1.311, whichever occurs first.
	(1)	The undersigned attorney certifies that each item of information contained in this
		Information Disclosure Statement was cited in a communication from a foreign
		patent office in a counterpart foreign application not more than three months prior
		to the filing of this statement;
	(2)	The undersigned attorney certifies that no item of information contained in this
		Information Disclosure Statement was cited in a communication from a foreign
		patent office in a counterpart foreign application or, to the knowledge of the
		undersigned attorney after making reasonable inquiry, was known to any
		individual designated in §1.56(c) more than three months prior to the filing of this
		statement; or
	(3)	This Information Disclosure Statement is accompanied by a transmittal letter in
		which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is
		authorized.

A concise explanation of the relevance of some or all of the items listed on the attached PTO-1449 (modified) is as follows:

The items listed on pages 1-13 of the attached PTO-1449 have been previously submitted to the Patent Office or cited by the Examiners during the prosecution of the following patents or patent applications commonly owned by the assignees of record of the present case:

U.S. Patent Nos. 6,576,630, 6,506,733, 6,455,502 and 6,492,362; and

U.S. Patent Application Nos. 10/035,783, 10/478,632, 10/787,367, 10/418,183 and 10/294,526.

Therefore, a copy of the reference is not enclosed with this Information Disclosure Statement. However, the applicant will furnish a copy of any listed reference, if so requested by the Examiner.

Respectfully submitted,

oseph Rossi, Reg. No. 47,038

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc. Patent Department

Route #202-206 / P.O. Box 6800

Bridgewater, NJ 08807-0800 Telephone (908) 231-3410

Telephone (908) 231-3410 Telefax (908) 231-2626

Aventis Docket No. USAV2001/0082 US CNT


		elgn (+) Inside this rork Reduction Act			Patent and Tradem	PTO/SB/09A (10-96) roved for use through 10/31/99. OMB 0651-0031 ark Office: U.S. DEPARTMENT OF COMMERCE 10 Unless it contains a valid OMB control number.
- (ute for form 1449A/				omplete if Known
	INC			201 001105	Application Number	10/719,080
				SCLOSURE	Filing Date	11-21-2003
	STA	ATEMENT	BY	APPLICANT	First Named Inventor	GRAUPE
					Group Art Unit	1626
١		(use as many :	sheets a	s necessary)	Examiner Name	Anderson, Rebecca
- (Sheet	1	of	13	Attorney Docket Number	USAV2001/0082 - US - CNT

				U.S. PATENT DOCI	JMENTS	
Examiner Initials*	Cite No.1	U.S. Patent Number	Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevem Passages or Relevant Figures Appear
-		4,927,609		STUBER, et al.	05-22-1990	
		5,424,325		ANDO, et al.	06-13-1995	
		5,486,623		ZIMMERMAN, et al.	01-23-1996	
		5,498,616		MALLANO, et al .	03-12-1996	
		5,847,135]	BEMIS, et al.	12-08-1998	•
		5,852,007		CHATTERJEE, et al.	12-22-1998	•••
		5,874,424		BATCHELOR, et al.	02-23-1999	···
		5,998,390		RAMAMURTHY, et al.	12-07-1999	
		6,004,933		SPRUCE, et al.	12-21-1999	<u> </u>
		6,022,861		SCARBOROUGH, et al.	02-08-2000	
		6,114,310		CHAMBERLAND, et al.	09-05-2000	
		6,124,333		MILLER, et al.	12-26-2000	
		6,255,453		GYORKOS	07-03-2001	
		6,353,017		ALTMAN, et al.	03-05-2002	
		6,455,502		BRYANT, et al.	09-24-2002	
		6,476,026		BRYANT, et al.	11-05-2002	
		6,492,362		GRAUPE, et al.	12-10-2002	
		6,508,733		BUYSSE	01-14-2003	
		6,576,630		LINK, et al.	06-10-2003	

				FOR	EIGN PATENT DOCUMENT	rs		
Examiner Initials*	Cite No.1	Office	Foreign Patent Do Number	cument Kind Code ¹ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Whore Relevant Passages of Relevant Figures Appear	Tê
		EP '	EP 0272671		KRANTZ, et al.	06-29-1988		\top
		EP	EP 0291234		EDWARDS, et al.	11-17-1998		
		EΡ	EP 0355572	1	PAQUES, et al.	02-28-1990		
		EP	EP 0376012		ALBRIGHT, et al.	07-04-1990		
		EP	EP 0419883		HARA, et al.	04-03-1991		o
		EP	EP 0536399		OKUBO, et al.	04-01-1993		T
		EP	EP 0652009		DOVEY, et al.	10-05-1995		\top
		EP	EP 0754454		KOBAYASHI, et al.	01-22-1997		\Box
		JP	JP 06192199		RYOICHI, et al.	07-12-1994		T
		JP	JP 42009133		IRIKURA, et al.	05-06-1967		T

Examiner	Date	
Signature	Considered	

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documenta. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese petent documents, the indication of the year of the reign of the Emperor must precede the seriel number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	sign (+) Inside this bo vork Reduction Act of	L	osrsons are required to re		PTO/SB/08A (10-96) PTO/SB/08A (10-96)
- (ute for form 1449A/PT				omplete if Known
INC	ODMATION		OLOGUES	Application Number	10/719,080
	ORMATION			Filing Date	11-21-2003
STA	ATEMENT B	BY A	PPLICANT	First Named Inventor	GRAUPE
				Group Art Unit	1626
	(use as meny she	ets as	necessary)	Examiner Name	Anderson, Rebecca
Sheet	2	of	13	Altomey Docket Number	USAV2001/0082 - US - CNT

				U.S. PATENT DOCL	JMENTS	
Examiner nilials	Cite No.1	U.S. Patent Number	Cocument Kind Codo ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		10/035,783		GRAUPE, et al.	12-24-2001	, , , , , , , , , , , , , , , , , , ,
		10/294,526		LI, et al.	11-14-2002	
		US02/17922		GRAUPE, et al.	11-24-2003	
		10/787,367		GRAUPE, et al.	9-16-2002	
		10/418,183		LI, et al.	10-29-2003	· · · · · · · · · · · · · · · · · · ·
						<u> </u>
	_					
		,				
		,				
						· · · · · · · · · · · · · · · · · · ·
			$\neg \neg$			
\neg				····		• • • • • • • • • • • • • • • • • • • •

				FOR	EIGN PATENT DOCUMEN	rs		
Externiner Initials*	Cile No.1	Office:	Foreign Patent Do	Kind Code ⁵	Name of Patenties or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	Ī.
				(if known)		MM-DD-YYYY	Figures Appear	T6
		JP	JP 63303868		YOSHIDA, et al.	12-08-1988		
		wo	WO 00/48992		TUCKER, et al.	08-24-2000		
		wo	WO 00/49007		TUCKER, et al.	08-24-2000		\top
		WQ	WO 00/49008		TUCKER, et al.	08-24-2000		
		wo	WO 00/51998		CYWIN, et al.	09-08-2000		
		WO	WO 00/59881		SINGH, et al.	10-12-2000		\top
		wo	WO 00/69855		QUIBELL, et al.	11-23-2000		
		wo	WO 01/09110		BEKKALI, et al.	02-08-2001		
		wo	WO 01/19796		GRAUPE, et al.	03-22-2001		
		wo	WO 01/19808		GRAUPE	03-22-2001		

Examiner	D	Date	· · · · · · · · · · · · · · · · · · ·
Signature	l c	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents, ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sortal number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		sign (+) inside this b vork Reduction Act o				PTO/SB/08A (10-96) proved for use through 10/31/99, OMB 0651-0031 park Office; U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number.
1	7	ute for form 1449A/P				omplete if Known
	INIC	ODSKATIO	u bi	CCL COURE	Application Number	10/719,080
1				SCLOSURE	Filing Date	11-21-2003
	STA	ATEMENT	BY A	APPLIÇANT	First Named Inventor	GRAUPE
		6			Group Art Unit	1626
1		(use as many sh	eets a	s necessary)	Examiner Name	Anderson, Rebecca
	Sheet	3	of	13	Attorney Docket Number	U\$AV2001/0082 - US - CNT

_				U.S. PATENT DOCI	JMENTS	
Examiner	miner Cite		t Document	Name of Patentee or Applicant	Date of Publication of	Pagos, Columna, Linea, Where Relevant
Initials*	No.1	Number	(if known)	of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
					 - 	
			1-1-		 	
						· · · · · · · · · · · · · · · · · · ·
					 	
-+					 	
						·
		-				
					 	
<u> </u>						
ightharpoonup						
	T				1 -	

~		•		FOR	EIGN PATENT DOCUMEN	rs		
Examiner Initials	Cita No.1	Office	Foreign Patent Do Number	Cument Kind Codo ² (If known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevent Passages or Rokevent Floures Appear	T ⁵
		wo	WO 01/19816		EMMANUEL, et al.	03-22-2001		
		WO	WO 01/30772		TUCKER, et al.	05-03-2001		\top
		WO	WO 01/55125		BOZSING, et al.	08-02-2001		\top
		WO	WO 01/58886		MISSBACH, M	08-16-2001	*	╅
		WO	WO 95/13069		MORRIELLO, et al.	05-18-1995		
		8	WO 95/15309		JENKINS, et al.	06-08-1995		1
		wo	WO 95/24382		HALLINAN, et al.	09-14-1995		\top
		wo	WO 96/21655		PEET, et al.	07-18-1996	· · · · · · · · · · · · · · · · · · ·	\top
		WO	WO 96/30353		PALMER, et al	10-03-1996		
		wo	WO 96/40847		ZIMMERMAN, et al.	12-19-1998	-	1

Examiner		Date	
Signature	<u> </u>	Considered	

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that Issued the document, by the two-letter odds (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the scriol number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of itme you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patente, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


	sign (+) Inside this to ork Reduction Act o	L	persons are required to re	Ap; Patent and Tradent apond to a collection of Informati	PTO/SB/08A (10-96) PTO/SB/08A (1
7	de for farm 1449A/P				complete if Known
INIE		N DIG	CLOSURE	Application Number	10/719,080
				Filing Date	11-21-2003
STA	TEMENT	BY A	PPLICANT	First Named Inventor	GRAUPE
	(***			Group Art Unit	1626
<u> </u>	(USA as many st	100IS 23	necessary)	Examiner Name	Anderson, Rebecca
Sheet	4	of	13_	Allomey Docket Number	USAV2001/0082 - US - CNT

				U.S. PATENT DOC	MENTS	
Examiner			t Document Kind Codo ²	Name of Patentee or Applicant	Date of Publication of	Pagos, Columns, Lines, Whore Relevant
nitials"	No.	Number	(if known)	of Cited Document	Citcd Document MM-DD-YYYY	Passages or Relevant Figures Appear
		<u> </u>				
	I					
						
				<u> </u>		
			- - 			
					ļ	 . ,,
	- 				-	
- 1	 		-+-		-	···
			- - 		 	
						· · · · · · · · · · · · · · · · · · ·
						
1		-	- 			
					-	· · · · · · · · · · · · · · · · · · ·
			- - -	<u> </u>	 	
		~	- - 		+	
			- - 		 	
						

	<u> </u>			FOR	EIGN PATENT DOCUMENT	ſS	·	***************************************
Examiner Inilials*	Cite No.1	Office	Foreign Petent Do Number4	cument Kind Code ^s (if known)	Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Tº
		wo	WO 96/40744		MARLOWE, et al.	12-19-1996		Т
100		wo	WO 96/41638		DOLLE, et al.	12-27-1996		\top
		wo	WO 97/03679		MALLANO, et al.	02-08-1997		1
		wo	WO 98/01133		AIBE, et al.	01-15-1998	`	
		S O	WO 98/01428		DOMINGUEZ, et al.	01-15-1998	· • •	\top
		S O	WO 98/05336		MARQUIS, et al.	02-12-1998	•	1
		WO	WO 98/08802		YAMASHITA, et al.	03-05-1998		1
		WO	WO 98/08867		SHIONOGI, et al.	03-05-1998		1
		wo	WO 98/21188		PRESTON, et al.	05-22-1998		\top
		wo	WO 98/23588		FLOYD, C.	06-04-1998		\top

	· · · · · · · · · · · · · · · · · · ·		
Examiner		Date	
Signature		Considered	

¹ Unique citation deelgnation number. ² See attached Kinda of U.S. Patent Documents. ⁸ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the sensi number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign Under the Panerwork I			rsons are required to n	App Patent and Tradem espection of Information	PTO/SB/08A (10-98) Proved for use through 10/31/99. OMB 0651-0031 Park Office: U.S. DEPARTMENT OF COMMERCE ON Unless (Conteins a valid OMB control number,
(or form 1449A/				omplete if Known
INFOR	ORA A TIO	N DICC	LOSURE	Application Number	10/719,080
				Filing Dato	11-21-2003
STAT	EMENT	BY AP	PLICANT	First Named Inventor	GRAUPE
///	0 an manua			Group Art Unit	1626
100	e as many s	neets as ne	essary)	Examiner Name	Anderson, Rebecca
Sheet	5	of	13	Attorney Docket Number	USAV2001/0082 - US - CNT

				U.S. PATENT DOCI	UMENTS	
Examiner Initials	Cite No.1	U.S. Pater Number	Kind Code ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Peges, Columns, Unea, Where Relevant Passages or Relevant Figures Appear
-+						
						
 [-						
	\dashv			<u> </u>		
	\dashv		- 			
	\neg					
					 	
—∔						
	-				.	
-+						
	\neg		- 			
	\dashv					
			1 1		1	·

				FOR	EIGN PATENT DOCUMENT	TS	· ·	
Examiner Initiala*	Cite No.1	Office	Foreign Patent Do Number	cument Kind Code [‡] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T\$
		wo	WO 98/49190		SPRUCE, et al.	11-05-1998		Т
		wo	WO 99/24460		ALTMANN, et al.	05-20-1999		
		-						-
								+
						 		
								1

Examiner	· -	Date	
Signature		Considered	1

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST, 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	us sign (+) Inside th work Reduction Ac			App Patent and Tradem Spond to a collection of informati	PTO/SB/08B (10-98) proved for use through 10/31/99. OMB 0651-0031 nark Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid QMB control number.
1	le for form 14498/F				omplete if Known
INEC	DAS A TIC	AL IS	ICOL COLIDE	Application Number	10/719,080
			ISCLOSURE	Filing Date	11-21-2003
STA	TEMENT	·BY	APPLICANT	First Namod Inventor	GRAUPE
				Group Art Unit	1626
<u> </u>	(use as man	y sheet	as necessary)	Examiner Name	Anderson, Rebecca
Sheet	6	of	13	Attorney Docket Number	USAV2001/0082 - US - CNT

	١	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the
Examiner initials"	Cite No.1	nem (book, magazine, journal, serial, symposlum, catalog. etc.), date, page(s), volume-lessue number(a), publisher, city and/or country where published.
		ADAMS, et al., Potent and Selective Inhibitors of the Proteasom: Dipeptidyl Boronic Acids, Biooganic & Medicinal Chemistry Letters, 8: 333-338 (1993).
		ASHWOFITH, et al., 4-Cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV, Bloorganic & Med. Chem. Letters, B,Oxford, 6(22):2745-2748 (1996).
		BERGEMAN, et al., Studies on the reactivity of .alphacyano.alpha-isocyano alkanoates. Versitile synthons for the assembly of imidazoles, Helv.Chim. ACTA, 82(6):909-918 (1999).
		BILLSON, et al., The Design and Synthesis of Inhibitors of the Cysteinyl , Bioorg, Med. Cham. Lett. vol. 8, pp. 993-998, 1998
		BROMME, et al., Potent Inactivation of Cathepsins S and L , Biol. Chem. Hoppe—Seyler. vol. 375, No. 5, pp. 343-347, 1994.
		CHATTERJEE, et al., D-Amino Acid Containing, High-Affinity Inhibitors of Recombinant Human Calpain I, Journal of Medicinal Chemistry, vol. 41, No. 15, pt 2663-2666 (1998).
		COHEN, et al., Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders, Journal of NeuroImmunology, 98: 29-36 (1999).
		DUFOUR, et al., Engineering nitrile hydratase activity into a cystelne protease by a single mutation, Bio.chemistry, US, Am. Chem. Soc., Easton, PA, 34(50):16382-16388 (1995).
		EDWARDS, et al., Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl a-Ketobenzoxazoles, and the X-ray Crystal Structure of the Covalent Complex between Porcine Pancreatic Elastase and Ac-Ala-Pro-Val-2-Benzoxazole, Journal of American Chemical Society, vol. 114, No. 5, p 1854-1863 (1992).
	\exists	EVOLI, et al., abstract only, Drugs, 1996, 52(5), 662-70

Examiner	Date
Signature	Considered

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	lus sign (+) Inside work Reduction A				proved for uso through 10/31/99, OMB 0651-0031 nark Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number.
(ute for form 1449B				omplete if Known
INC	ODREATIE	~ N =	VICOL COURT	Application Number	10/719,080
	NFORMATION DISCLOSUS		Filing Date	11-21-2003	
STA	TEMEN	T BY	APPLICANT	First Named Inventor	GRAUPE
				Group Art Unit	1626
<u> </u>	(use as mai	ny sheel	s as necessary)	Examiner Name	Anderson, Rebecca
Sheet	7	of	13	Attorney Docket Number	USAV2001/0082 - US - CNT

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Inidals*	Cite No.1	Include name of the author (in CAPITAL LETTERS), tile of the article (when appropriate), tille of the liem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	τ
		GOUR-SALIN, et al., Inhibition of papain by peptide nitriles: conversion of the nitrile group into other functionalities via the papain:nitrile thiomidate ester adduct, Can. J. of Chem, CA, National Research Council. Ottawa, 69(8):1288-1297 (1991).	
-		HALLEGUA, et al., Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature, Lupus, 9: 241-251 (2000).	
		HANZLIK, et al., Reversible covalent binding of peptide nitriles to papain, Biochim. Biophye, Acta, vol. 1035, No. 1, 1990, pp. 62-70.	
		HARRIS, et al., Characteristics of a continuous fluorogenic assay for calpain I. Kinetic evaluation of peptide aldehydes, halomethyl ketones and)achalasia) methyl ketones as inhibitors of the enzyme, Chemical Abstracts, 110:7, Bioorg. Med. Chem. Lett. 5(4) 393-398 (1995).	
		HEITMILLER, R.F., abstract only., Semin. Thorac. Cardiovasc. Surg., 1999, 11(1), 41-6	-
		KATRITZKY, et al., Benzotriazole-assisted synthesis of alpha(acytamino) nitrites and a conceptually novel method for peptide elongation, Chem. Soc., Perkin Trans. 1(7):1853-1857 (1990).	
		KHAMASHTA, et al., Expert. Opin. Investig. Drugs, 2000, 9(7), 1581-93.	
		KRANTZ, et al., Peptidyl (Acyloxy)methyl Ketones and the Quiescent , Biochemistry, vol. 30, pp. 4678-4687, 1991	
		LEVY, E.G., Ballileres Clin. Endocrinol. Metab., 1997, 11(3) 585-595	
		Lt, et al., Aminoacylpyrrolldine-2-nitriles; Potent and stable inhibitors of dipeptidyl-peptidase IV (CD 26), Archives of Blochem. and Bioph., 323(1)148-154 (1995).	

Examiner		Date	
Signature	<u> </u>	Considered	
· · · · · · · · · · · · · · · · · · ·			

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	us sign (+) inside the work Reduction Act		· 🗀		PTO/SB/08B (10-95) proved for use through 10/31/99, OMB 0651-0(31 park Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number.
(le for form 1449B/P				Omplete if Known
INF	DREATIO	NI P	IOOL OOUBE	Application Number	10/719,080
INFO	JRIMATIO	N L	ISCLOSURE	Filing Date	11-21-2003
STA	TEMENT	BY	APPLICANT	First Named Inventor	GRAUPE
				Group Art Unit	1626
	(use as many	sheet	s as necessary)	Examiner Name	Anderson, Rebecca
Sheet	8	of	13	Attorney Docket Number	USAV2001/0082 - US - CNT

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	_
Examiner Inklals	Cite No.1	Include name of the author (in CAPITAL LETTERS), tide of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7
		LIPSHUTZ, et al., Chiral induction in orginally recemic amino acids via 5-acyl and 5-acyloxyaminooxazoles, Isr, J. Chem. 27(1):49-55 (1986), abstract.	
		LIPSHUTZ, et al., Heterocycles as masked diamide/dipeptide equivalents. Formation and reactions of substituted 5-(acylamino)oxazoles as intermediates en route to the cyclopeptide alkaloids, . Am. Chem. Soc., 105(26):7703-7713 (1983).	
		LIPSHUTZ, et al., Oxazolophanes as masked cyclopeptide alkaloid equivalents: cyclic peptide chemistry without peptide couplings, J. Am. Chem. Soc., 112(19):7032-7041 (1990).	
,		MARQUIS, et al., Potent dipepticylketone inhibitore of the cystelne protease cathepsin, Chemical Abstracts, 7:4 581-588 (1999).	
		MCMATH, et al., Direct dialkylation of peptide nitrites. Application of the synthesis of 1-aminocyclopropane-1 carboxylic acid (Acc)-containing dipeptides, Bull. Soc. Chim. Fr. 134(1):105-110 (1997),	
		MORIYA, et al., Synthesis and Hypolipidemic Activities of 5-Thienyl-4-oxazoleacetic Acid Derivatives.sup.1, J. Med. Chem., 29: 333-341 (1986).	
		MOSER, et al., 130 Poly (dipeptamidinium)-Salze: definition und metoden zur praparativen herstellung. poly (dipeptamidinium) salts: definition and methods of preperation, Helvitica Chimica ACTA, CH, Verlag, Basel 69:1224-1262 (1986).	
		NIPPON, K., Patent Abstracts of Japan, Publication No. 63301868, 013(137)(1988), abstract.	
		NORTH, et al., Synthetic studies towards cyclic peptides. Concise synthesis of thiazollne and thiazole containing amino acids, Tetrahedron, 46(24):8627-8290 (1990).	
		OGILVIE, et al., Peptidomimetic inhibitors of the human cytomegalovirus protease, Journal of Medicinal Chemistry vol. 40 No. 25 (1997).	

,			
Examiner		Date	
Signature		 Considered	
	 		_

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Tradement Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		us sign (+) inside t work Reduction A		·	Datest and Tender	PTO/SB/06B (10-96) proved for use through 10/31/98. OMB 0651-0031 nerk Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number.	
1		ite for form 14498/				omplete if Known	١
					Application Number	10/719,080	t
ı	INF	DRMATIC	ם אכ	ISCLOSURE	Filing Date	11-21-2003	t
ŀ	STA	TEMENT	BY	APPLICANT	First Named Inventor	GRAUPE	1
				, ,,	Group Art Unit	1626	t
L		(use as mar	ny sheet:	s as necessary)	Examiner Name	Anderson, Rebecca	I
┖	Sheet	9	of	13	Aftorney Docket Number	USAV2001/0082 - US - CNT	j

	1	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	_
nitiala*	Cile No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, scriat, symposium, catalog, etc.), date, page(e), volume-lasue number(s), publisher, city and/or country where published.	7
		PICKEN, et al., Inhibition of bovine cathepsin B by amino acid-derived nitrites, Biochemical Society Transactions, vol. 18, No. 2, p:316 (1990).	
		PLIURA, et al., Comparative behavior of colpain and cathepsin B , Biochem. J. vol. 288, pp. 759-762, 1992	
		POLMAN, et al., Drug treatment of multiple sclerosis , BMJ, 321: 19-26 (2000).	
		RIESE, et al., Essential Role for Cathesin S in MHC Class II-Associated Invariant Chain Processing and Peptide Loading, Immunity, 4: 357-366 (Apr. 1996).	
		SMITH, et al., New Inhibitors of Cysteine Proteinases, J. Am. Chem. Soc. vol. 110, No. 13, pp. 4429-4431, 1988	
<u>-</u>		SUAVE, et al., Carboxylmodified amino acids and peptides, I An efficient method for the synthesis of monofuntionalized enamines and monofuntionalized methyl ketone derivatives fom thioamides via episulfides and thioiminium ealts, Tetrahedron Lett, 29:19 2295-2298 (1988).	_
		SUZUE, S., Hepatic agents. I. Synthesis of aminocyl (and hydroxyacyl) aminoacetonitriles, Chem. and Pharm. Bull. (Tokyo) (1968), 16(8), 1417-32.	
		SUZUE, et al., Studies on Heptio Agents , Chem. Pharm. Bull. vol. 16, No. 8, pp. 1417-1432, Aug. 1968.	
		SUZUKI, et al., Synthesis of 2-Aryl-4(3-thlenyl)imidazole Derivatives with Antinflammatory Properties .sup.1), Chem. Pharm. Bull, 34(8): 3111-3120 (1998).	
		TAO, st al., Inhibition of Calpain By Peptidyl Heterocycles, Bioorganic & Medicinal Chemnistry Letters, 6:24 3009-3112 (1998).	

Examiner	Date
Signature	Considered

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	us sign (+) inside th work Reduction Act	•	l	Potent and Toodom	PTO/SB/08B (10-98) proved for use through 10/31/99. OMB 0651-0031 lark Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number,
	te for form 1449B/F				omplete if Known
1				Application Number	10/719,080
INFC	PRIMA NC	ט אל	ISCLOSURE	Filing Date	11-21-2003
I STA	TEMENT	BY	APPLICANT	First Named Inventor	GRAUPE
		– . .		Group Art Unit	1626
	(use as man	y sheets	as necessary)	Examiner Name	Anderson, Rebecca
Sheet	10	of	13	Attorney Docket Number	USAV2001/0082 - US - CNT

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	Т
Examiner Initials	Cite No.1	ltem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		THOMPSON, et al., Carboxyl-modified amino acids and peptides as protease inhibitors, J. Med. Chem., 29(1):104-111 (1986).	
		TSUTSUMI, et al., Synthesis and Structure-Activity Relationships of Peptidyl a-Keto Heterocycles as Novel Inhibitors of Prolyl Endopeptidase, Journal of Medicinal Chemistry, vol. 37, No. 21, p 3492-3502 (1994).	
	1	VARGHA, E., Peptide derivatives. VI. N-protected di- and tripeptide nitriles, Stud. Univ. Babes-Bolyal, Ser. Chem., 13(2):31-5 (English abstract of article in Romanian) (1968).	-
		VARGHESE, The structure and resonance Raman spectra-structure correlations for methyloxycarbonyl-L-phenylalanyl-L-alanine ethyl dithioester, Can. J. Chem., 64(8):1668-1673 (1988).	
		YAMADA, et al., Studies of unusual amino acids and their peptides. IX. The synthetic study of bottomycins B1 and B2, Bul. Chem. Soc., Jpn. 51(3):878-83 (1978), abstract.	
		, Derwent Abstract of Japanese Patent Application 06-192199 , (Jul. 12, 1994).	
			
Examine	<u> </u>	Date	<u> </u>

Examiner	Date	
Signature	Considered	
		· · · · · · · · · · · · · · · · · · ·

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the IndMidual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		sign (+) inside this ork Reduction Act		en de periupor are enom	Patent and Tradem	PTO/SB/08A (10-9 proved for use through 10/31/89. OMB 0651-00 ank Office: U.S. DEPARTMENT OF COMMERC On unless it contains a valld OMB control number	31
- (ile for form 1449A				omplete if Known	
	1517		M DIGG		Application Number	10/719,080	7
ı				LOSURE	Filing Date	11-21-2003	7
l	STA	TEMENT	BY AP	PLICANT	First Named Inventor	GRAUPE	\neg
ŀ					Group Art Unit	1626	\neg
(use as many sheets as necessary)				cessary)	Examiner Name	Anderson, Rebecca	
- (Sheet	11	of	13	Altorney Docket Number	USAV2001/0082 - US - CNT	7

				U.S. PATENT DOCU	JMENTS	
Examiner Initials*	Cite No.¹	U.S. Patent Number	Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pagos, Columns, Lines, Where Relovant Passages or Relevant Figures Appear
		09/927,188		CAI, et al.	08-10-2001	
		09/927,324		BUTLER, et al.	08-10-2001	· ·
		09/928,122		BREITENBUCHER, et al.	08-10-2001	
		09/946,214		GU, et al.	09-05-2001	
		10/042,565		QUIBELL, et al.	11-16-2001	
		10/148,612		OHMOTO, et al.	08-21-2002	
		10/148,613		OHMOTO, et al.	08-28-2002	
		10/181,713		OHMOTO, et al.	07-22-2002	
		10/181,799		OHMOTO, et al.	07-23-2002	
		10/231,425		BUXTON, et al	08-28-2002	
		10/256,512		BEKKALI, et al.	09-27-2002	
		10/258,059		CUMMINGS, et al.	10-17-2002	
		10/275,583		COWEN, et al.	11-07-2002	
		10/279,424		BEKKALI, et al.	10-24-2002	•
		10/466,385		QUIBELL, et al.	01-08-2004	
		6,015,791		GYORKOS, et al.	01-18-2000	₩
		6,608,057		CYWIN, et al.	08-18-2003	
						,

				FOR	EIGN PATENT DOCUMEN	rs		
Exeminer Initials*	Cite No.1	Office	Foreign Patent Doc Number ⁴	ument Kind Code ^s (if known)	Name of Patentae or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Whore Relevant Passages or Relevant	T ₅
		JP	JP 2001-011037	Çi 2.151/11	SATO, et al.	MM-DD-YYYY 01-16-2001	Figures Appear	+ 12
		JP	JP 2001-055366		SATO, et al.	02-27-2001		\top
		wo	WO00/59881		SINGH, et al.	10-12-2000		1
		WO	WO01/09169		SINGH, et al.	02-08-2001		1
		WO	WO02/057248		QUIBELL, et al.	07-25-2002		7
		WO	WO02/057249		QUIBELL, M	07-25-2002		T
		wo	WO02/057270		QUIBELL, M	07-25-2002	<u> </u>	1
		WO	WO02/096892		OHMOTO, et al.	05-30-2002		1
		wo	WO02/100849		HICKEY, et al.	12-19-2002		1
		wo	WO02/20485		BEKKALI, et al.	03-14-2002		

Examiner	 Date	***
Signature	Considered	
	00113100100	

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the rolgn of the Emperor must precade the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Tradement Office. Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	s sign (+) inside thi ork Reduction Act			Potent and Tmelom	PTO/SB/08B (10-98) proved for use through 10/31/99. OMB 0831-0041 park Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number.		
	e for form 14498/P			Complete if Known			
	D11.7.0			Application Number 10/719,080			
INFO	IRMAHO	NL	DISCLOSURE	Filing Date	11-21-2003		
STA"	TEMENT	BY	APPLICANT	First Named Inventor	GRAUPE		
			, .,	Group Art Unit	1626		
	(use as many	sheet	's as necessary)	Examiner Name	Anderson, Rebecca		
Sheet	12	of	13	Attorney Dockel Number	USAV2001/0082 - US - CNT		

	1	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	_						
	Cite No.1								
		CHAPMAN, et al., Emerging Roles for Cysteine Proteases in Human Blology, Ann. Rev. Physiol.; 1997; 59; pp.63-88.							
····		DRANOFF, et al., Cathepsin S Required for Normal MHC Class II Peptide Loading and Germinal Center Development, Immunity; 1999; 10; pp.197-208.							
		FENWICK, et al., Diastereoselective Synthesis, Activity and Chiral Stability of Cyclic Alkoxyketone Inhibitors of Cathepsin K., Bioorg. Med. Chemm. Lett.; 2001; 11(2); pp.199-202.							
		FENWICK, et al., Solid-phase Synthesis of Cyclic Alkoxyketones, Inhibitors of the Cystelne Protease Cathepsin K., Bloorg. Med. Chem. Lett.; 2001; 11(2); pp.195-198.							
		GREENSPAN, et al., Identification of Dipeptidyl Nitriles as Potent and Selective Inhibitors of cathepsin B Through Structure-based Drug Design, J. Med. Chem.; 2001; 44; pp.4524-4534.							
		LOWE, et al., Kinetic Specificity in Papain-catalyzed Hydrotyses, Biochem. J.; 1971; 124(1); pp.107-115.							
		MACIEWICZ, et al., A comparison of Four Cathepsins (B,L,N and S) with Collagenolytic Activity From Rabbit Spleen, Biochem J.; 1998; 256; pp.433-440.							
		MARQUIS, et al., Azeanone-based Inhibitors of Human and Rat Cathepsin K., J. Med. Chem.; 2000; 44(9); pp.1380-1395.							
		NAKAGAWA, et al., Imparied Invariant Chain Degradation and Antigen Presentation and Diminished Collagen-Induced Arthritis in Cathepsin S-null Mice, Immunity; 1999; 10; pp.207-217.	_						
		OTTO, et al., Cysteine Proteases and their Inhibitors, Chem. Rev.; 1997; 97; pp.133-171.							

	The second secon		
Examiner		Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

	s sign (+) inside th ork Reduction Ac	_	persons are required to re	Dotant and Teddom	PTO/SB/08B (10-96) proved for use through 10/31/99. OMB 0651-0031 sark Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid CMB control number.
Substitute	for form 1449B/F	οτο		Co	omplete if Known
	D11 1 71 6			Application Number	10/719,080
INFO	RMATIC	on dis	CLOSURE	Filing Date	11-21-2003
STA	TEMENT	BY A	PPLICANT	First Named Inventor	GRAUPE
		_,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,	Group Art Unit	1626
	(use as man	y sheets as	necessary)	Examiner Name	Anderson, Rebecca
Sheet	13	of	13	Altomay Docket Number	USAV2001/0082 - US - CNT
			•	-	

· · ·	-	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), little of the article (when appropriate), title of the							
		SHI, et al., Molecular Cloning and Expression of Human Alveolar Macrophage Cathepsin S, an Elastinolytic Cysteine Protease, J. Biol. Cham.; 1992; 267; pp.7258-7262.							
		SINGH, et al., beta-lactams as Enzyme Inhibitors., IDrugs; 2000; 3(5); pp.512-517.							
		VILLADANGOS, et al., Cathepsin S Activity Regulates Antigen Presentation and Immunity, J. Clin. Invest.; 1998; 101(10); pp.2351-2363.							
									
		· · · · · · · · · · · · · · · · · · ·							
Examine Signature		Date Considered							

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the includival case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 3 Applicant is to place a check mark here If English language Translation is attached.